Concepedia

Author

Ryan Geschwindt

Incyte (United States)

Also Known As

R Geschwindt, Ryan D Geschwindt, Ryan D. Geschwindt, Ryan Geschwindt

26

Publications

430

Citations

10

H-Index

19

Concepts

All Affiliations

Incyte (United States)The University of Texas MD Anderson Cancer CenterUniversity of PennsylvaniaSarah CannonInstitut Gustave Roussy
RG

About

Ryan Geschwindt is an author at Incyte (United States) specializing in medicine, cancer therapeutics, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

80

2

Immunology

2

2

58

3

Health Sciences

1

1

22

4

Cell Biology

1

1

16

5

Hepatology

1

1

16

Ryan Geschwindt

×

9

Publications

336

Citations

9

H-Index

YearCitations

MESOMARK™: A Potential Test for Malignant Pleural Mesothelioma

Heather L Beyer, Ryan Geschwindt, Curtis L. Glover,

Clinical Chemistry

2007

141

A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation

Joyce O’Shaughnessy, Angela DeMichele, X. Cynthia,

Breast Cancer Research and Treatment

2018

42

Detection of Newly Diagnosed Bladder Cancer, Bladder Cancer Recurrence and Bladder Cancer in Patients with Hematuria Using Quantitative RT-PCR of Urinary Survivin

Daniel M. Kenney, Ryan Geschwindt, Marcia R. Kary,

Tumor Biology

2007

35

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors

Andrew D.J. Pearson, Sara M. Federico, Isabelle Aerts,

Oncotarget

2016

28

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors

Jason J. Luke, Marwan Fakih, Charles Schneider,

British Journal of Cancer

2023

27

Phase 1 study of dalotuzumab monotherapy and ridaforolimus–dalotuzumab combination therapy in paediatric patients with advanced solid tumours

Didier Frappaz, Sara M. Federico, Andrew D.J. Pearson,

European Journal of Cancer

2016

22

Hepatitis B Virus MHBs Antigen Is Selectively Sensitive to Glucosidase-Mediated Processing in the Endoplasmic Reticulum

Xuanyong Lu, Yefei Lu, Ryan Geschwindt,

DNA and Cell Biology

2001

16

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study

Aung Naing, John D. Powderly, John Nemunaitis,

Journal for ImmunoTherapy of Cancer

2022

14

529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors

Eric Van Cutsem, Hans Prenen, Brant Delafontaine,

Regular and Young Investigator Award Abstracts

2021

11

Page 1